Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)

Benign Prostatic Hyperplasia Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03297398
• Other study ID #: SAR-202
• Status: Terminated
• Phase: Phase 2
• Start date: February 21, 2018
• Est. completion date: June 10, 2019

Study information

• Verified date: August 2021
• Source: OPKO Health, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety and effectiveness of different doses of OPK-88004 compared to placebo on serum PSA compared to placebo in men with benign prostatic hyperplasia (BPH).

Description:

Study SAR-202 is a phase 2 multicenter, placebo-controlled, double-blind trial to evaluate the effect of OPK-88004 doses (OPK-88004 15 mg, or OPK-88004 25 mg) on serum PSA compared to placebo in men with BPH. Approximately 115 men with BPH will be enrolled in the study, randomized 1:1:1 across three arms (placebo, OPK-88004 15 mg, or OPK-88004 25 mg). The trial will be conducted at approximately up to 35 sites within the US.

The study duration for individual subjects will be up to 24 weeks and will include three phases:

• a screening period (up to 4 weeks, including 1-week washout if required),

• a treatment period (16 weeks), and

• a follow-up period (4 weeks) Subjects will be randomized and receive their first dose of study drug at visit 2. They will begin the once daily oral dosing regimen and return every 4 weeks to the study site during the 16-week treatment period. Assessments during the study period will include vital signs, laboratory testing, weight, adverse events (AEs), concomitant drugs, and study drug compliance. Efficacy assessments will include serum PSA, LBM and fat mass by DXA scans, uroflowmetry parameters, PVR (by ultrasound), and assessment of symptoms by IPSS.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 114
• Est. completion date: June 10, 2019
• Est. primary completion date: April 18, 2019
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 45 Years and older

Eligibility

Inclusion Criteria

Subjects are eligible if they meet the following criteria:

1. Present with BPH-LUTS based on disease diagnostic criteria at visit 1

2. Are men aged 45 years or older at visit 1

3. Have prostate volume >40 cm3 and <80 cm3 assessed by TRUS at visit 1

4. Have a PSA >1.5 and <10.0 ng/mL at visit 1. This PSA blood draw must be performed at least 1 week after any digital rectal exam (DRE) and/or transrectal ultrasound (TRUS) procedures

5. Subjects with a PSA =4.0 and <10.0 ng/mL must have documentation of a negative histologic biopsy of carcinoma of the prostate within 12 months of screening (visit 1). For subjects aged =80 years and who have not undergone any invasive urological procedure within 6 months, if biopsy has not been performed, then 4Kscore Test value must be <7.5% at visit 1

6. Have laboratory tests within normal limits (with the exception of total serum or free testosterone). If laboratory test results are outside normal limits they are determined to be not clinically significant at visit 1

7. Have not received prior treatment with 5-ARIs (finasteride, dutasteride) within the past one year for any indication

8. Have not received herbal BPH preparations within 1 week of visit 1. If the subject is currently on such treatment, a 1-week washout period will be required

9. Agree not to use 5-ARIs, herbal or experimental treatments for BPH, at any time during the study. Subjects on daily PDE5i's, alpha-blockers or anticholinergic medications for BPH should remain on a stable dose during the study, unless a change in dose is medically warranted. Occasional-use PDE5i's for ED are permitted at a stable dose and frequency, however should not be taken within 72 hours prior to a study visit

10. Agree to use an acceptable method of birth control during the study and for 60 days after the last dose of IP, unless the female partner is postmenopausal. Postmenopausal is defined as a female >50 years of age and 12 months of amenorrhea, or surgically postmenopausal

11. Are reliable and willing to make themselves available for the duration of the study, and who will comply with the required study and dosing visits and abide by the Clinical Research Site policy and procedure and study restrictions

12. Have given written informed consent

Exclusion Criteria

Patients will be excluded from study enrollment if they meet any of the following criteria at visit 1:

1. History of any of the following pelvic conditions:

• radical prostatectomy, pelvic surgery for removal of malignancy, or bowel resection

• pelvic radiotherapy

• any pelvic surgical procedure on the urinary tract, including transurethral resection of the prostate (TURP), penile implant surgery

• lower urinary tract malignancy or trauma

• pelvic surgery or any other pelvic procedure less than 6 months prior to visit 1

2. Lower urinary tract instrumentation (including prostate biopsy) within 6 weeks prior to screening PSA blood draw

3. History of urinary retention or lower urinary tract (bladder) stones within 1 month of visit 1

4. Minimally invasive procedures for BPH, such as prostatic stent, high intensity focused ultrasound (HIFU), holmium laser enucleation of prostate (HoLEP), interstitial laser coagulation (ILC), transurethral electroevaporation of the prostate (TUVP), transurethral microwave thermotherapy (TUMT), transurethral needle ablation (TUNA), photoselective vaporization (PVP), UroLift, within 6 weeks

5. Clinical evidence of urinary tract infection or urinary tract inflammation (including prostatitis)

6. Intravesical obstruction (eg, intravesical median lobe of the prostate)

7. Current neurologic disease or condition associated with neurogenic bladder (eg, Parkinson's disease, multiple sclerosis)

8. History of significant renal insufficiency, defined as receiving renal dialysis or having an estimated creatinine clearance <45 mL/min

9. Active hepatobiliary disease or serologic evidence of active hepatitis A, B, C, hepatitis E or HIV

10. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 2X the upper limit of normal (ULN)

11. Glycosylated hemoglobin (HbA1c) >9%

12. Hematocrit =50%

13. HDL-C <35 mg/dL and LDL-C >130 mg/dL

14. QTcB interval >450 msec. For heart rates over 75, the ECG may be repeated after 5 minutes of resting quietly

15. Abnormality in ECG (eg, left bundle branch block, complete right bundle branch block, or delayed intraventricular conduction with a QRS interval >120 msec) that in the opinion of the investigator places the subject at an unacceptable risk for study participation, or subject has implanted pacemaker

16. History of any of the following cardiac/coronary conditions within 90 days:

• history of myocardial infarction or coronary artery bypass graft

• percutaneous coronary intervention

• stroke

17. Any evidence of heart disease (NYHA =Class II, Appendix 4) within 6 months, or are receiving treatment for congestive heart failure (CHF)

18. Any supraventricular or ventricular arrhythmia with uncontrolled ventricular response (mean heart rate >100 bpm) at rest despite medical therapy

19. Systolic blood pressure >160 or <90 mm Hg or diastolic blood pressure >100 or <50 mm Hg as determined by a sitting measurement (if stress is suspected, retest up to two times under basal conditions), or malignant hypertension

20. Have a history or presence of prostatic carcinoma, as well as any conditions that may be exacerbated by androgenic medications such as (but not limited to) epilepsy, seizures, convulsions, migraine or polycythemia

21. History of cancer within the previous 5 years, except for excised super?cial lesions (such as basal cell carcinoma and squamous cell carcinoma of the skin)

22. History of drug, alcohol, or substance abuse within 6 months

23. Have an alcohol intake of =3 units/day or =14 units/week during the study (1 unit = 12 ounces of beer, 5 ounces of wine, 1.5 ounces of distilled spirits)

24. Any condition that would interfere with subject's ability to provide informed consent or comply with study instructions, would impair ability to perform the study assessments, or would place subject at increased risk, or might confound the interpretation of the study results

25. Current treatment with androgens, antiandrogens, estrogens, or anabolic steroids within the prior 1 month. Any prior or current treatment with LHRH agonists/antagonists

26. Current treatment with potent CYP3A4 inhibitors such as itraconazole or ritonavir

27. Have taken prescription or over-the-counter medications to promote weight loss within the prior 3 months

28. Any prior use of OPK-88004 Allergic to any component of OPK-88004

Related Conditions & MeSH terms

• Benign Prostatic Hyperplasia
• Hyperplasia
• Prostatic Hyperplasia

Intervention

Drug:
• Group-1 (15mg, OPK-88004)
15mg, OPK-88004
• Group-2 (25 mg,OPK-88004)
25 mg,OPK-88004

Other:
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Pinnacle Research Group	Anniston	Alabama
United States	South Florida Medical Research	Aventura	Florida
United States	Centennial Medical Group	Elkridge	Maryland
United States	AccuMed Research Associates	Garden City	New York
United States	Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville	Knoxville	Tennessee
United States	Clinical Trials Research	Lincoln	California
United States	Advanced Clinical Research - Boise	Meridian	Idaho
United States	APF Research, LLC	Miami	Florida
United States	Manhattan Medical Research Practice PLLC	New York	New York
United States	Northern California Research	Sacramento	California
United States	Clinical Trials of Texas, Inc.	San Antonio	Texas
United States	Regional Urology	Shreveport	Louisiana
United States	Meridien Research - Brooksville	Spring Hill	Florida
United States	Florida Urology Partners	Tampa	Florida
United States	Bayview Research Group, LLC - Valley Village	Valley Village	California

Sponsors (1)

Lead Sponsor	Collaborator
OPKO Health, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Peak Flow Rate (Qmax)	Analysis peak flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16	16 weeks
Other	To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Mean Flow Rate (Qave)	Analysis mean flow rate of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16	16 weeks
Other	To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter-voided Volume (Vcomp)	Analysis voided of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16	16 weeks
Other	To Evaluate the Effect of OPK-88004 on Uroflowmetry Parameter- Postvoid Residual Volume (PVR)	Analysis postvoid residual volume of Uroflowmetry Parameters and Postvoid Residual Volume Observed Change from Baseline to Week 16	16 weeks
Other	International Prostate Symptom Score- IPSS	To evaluate the effects of OPK-88004 on the symptoms of BPH as determined by International prostate symptom score (IPSS score), Total IPSS score as measured by the sum of questions 1 through 7, the IPSS Irritative Domain (sum of questions 2, 4 and 7), and the IPSS Obstructive Domain (sum of questions 1, 3, 5 and 6)IPSS QoL question (IPSS question 8). Mild (symptoms score less than or equal to 7), moderate (symptoms score range 8-19), severe (symptom score 20-35)	16 weeks
Primary	Change From Baseline in PSA (%) to Week 16	The trial will evaluate the effect of two doses of OPK-88004 (15 mg and 25 mg) daily for 16 weeks on serum PSA compared with placebo	16 weeks
Secondary	Absolute Change in Lean Body Mass and Fat Mass From Baseline to 16 Weeks	To assess the effect of OPK-88004 on body composition by DXA, specifically Lean Body Mass (LBM) and fat mass	16 weeks